AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3166930 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebuhaler technique with five breaths sufficient to operate the Nebuhaler valve
Number of subjects: 13
Study 3166930 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebuhaler technique with two deep inspirations from residual volume held for 5 seconds
Number of subjects: 13
Study 3166930 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 31916633 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-directed learning (self-evaluation)
Number of subjects: 110
Study 31916633 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer feedback (peer evaluation)
Number of subjects: 110
Study 31916633 — intervention group
Group type: COMPARATOR
Intervention: Expert feedback
Number of subjects: 110
Study 31392991 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Strength Integration (FSI) intervention
Number of subjects: 100
Study 31392991 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON) with standard of care exercise program
Number of subjects: 100
Study 28861513 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency management (CM) for alcohol
Number of subjects: 121
Study 28861513 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabis users
Number of subjects: 121
Study 28861513 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabis use
Number of subjects: 121
Study 25287214 — intervention group
Group type: EXPERIMENTAL
Intervention: Ponesimod 40 mg
Number of subjects: 0
Study 25287214 — intervention group
Group type: EXPERIMENTAL
Intervention: Ponesimod 100 mg
Number of subjects: 0
Study 25287214 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Number of subjects: 0
Study 25287214 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23597235 — intervention group
Group type: EXPERIMENTAL
Intervention: Gardening intervention including a fruit and vegetable garden, monthly curriculum, gardening support, and technical assistance
Number of subjects: 6
Study 23597235 — intervention group
Group type: COMPARATOR
Intervention: Control centers (no gardening intervention)
Number of subjects: 6
Study 23597235 — intervention group
Group type: EXPERIMENTAL
Intervention: Gardening intervention
Number of subjects: 6
Study 23597235 — intervention group
Group type: COMPARATOR
Intervention: Control centers
Number of subjects: 6
Study 21658030 — intervention group
Group type: EXPERIMENTAL
Intervention: Utilitarian priming
Number of subjects: 0
Study 21658030 — intervention group
Group type: COMPARATOR
Intervention: Hedonic priming
Number of subjects: 0
Study 18359420 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician judgment of VAP probability at the time of CSVAP
Number of subjects: 740
Study 18359420 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrospective adjudication of VAP
Number of subjects: 740
Study 18359420 — intervention group
Group type: EXPERIMENTAL
Intervention: CSVAP occurrence >7 days after start of mechanical ventilation
Number of subjects: 740
Study 18359420 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative index cultures
Number of subjects: 740
Study 18359420 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacteremia
Number of subjects: 740
Study 16522412 — intervention group
Group type: EXPERIMENTAL
Intervention: Valacyclovir 500 mg twice daily until delivery
Number of subjects: 112
Study 16522412 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study 12771610 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous enoxaparin 40 mg daily
Number of subjects: 29
Study 10695617 — intervention group
Group type: COMPARATOR
Intervention: LAC (lansoprazole 30 mg twice a day, amoxicillin 500 mg three times a day, clarithromycin 200 mg twice a day)
Number of subjects: 308
Study 10695617 — intervention group
Group type: EXPERIMENTAL
Intervention: RAC (rabeprazole 20 mg twice a day, amoxicillin 500 mg three times a day, clarithromycin 200 mg twice a day)
Number of subjects: 308
Study 10695617 — intervention group
Group type: EXPERIMENTAL
Intervention: R1/2AC (rabeprazole 10 mg twice a day, amoxicillin 500 mg three times a day, clarithromycin 200 mg twice a day)
Number of subjects: 308
Study 9352986 — intervention group
Group type: EXPERIMENTAL
Intervention: Norvasc (Amlodipine)
Number of subjects: 0
Study 9352986 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid ultrasound examinations
Number of subjects: 0
Study 1347801 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin plus heparin
Number of subjects: 41299
Study 1347801 — intervention group
Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 41299
Study 1347801 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase (SK)
Number of subjects: 41299
Study 1347801 — intervention group
Group type: COMPARATOR
Intervention: Anistreplase (APSAC)
Number of subjects: 41299
Study 3915886 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenoxicam 20 mg
Number of subjects: 30
Study 3915886 — intervention group
Group type: COMPARATOR
Intervention: Piroxicam 20 mg
Number of subjects: 30
Study 3915886 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenoxicam (continued treatment)
Number of subjects: 30
Study 3915886 — intervention group
Group type: COMPARATOR
Intervention: Piroxicam (switched to tenoxicam)
Number of subjects: 30
Study 3915886 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenoxicam and Piroxicam
Number of subjects: 30
Study 3915886 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenoxicam
Number of subjects: 30
Study 31022704 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic group (Streptococcus salivarius M18)
Number of subjects: 64
Study 31022704 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 64
Study 30265040 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent Treatment of PTSD and SUD Using Prolonged Exposure (COPE)
Number of subjects: 0
Study 30265040 — intervention group
Group type: EXPERIMENTAL
Intervention: Relapse Prevention Therapy (RPT)
Number of subjects: 0
Study 25972081 — intervention group
Group type: EXPERIMENTAL
Intervention: PRF/DFDBA
Number of subjects: 30
Study 25972081 — intervention group
Group type: COMPARATOR
Intervention: DFDBA/saline
Number of subjects: 30
Study 25024230 — intervention group
Group type: EXPERIMENTAL
Intervention: Strabismus
Number of subjects: 0
Study 25024230 — intervention group
Group type: EXPERIMENTAL
Intervention: Anisometropia
Number of subjects: 0
Study 22686162 — intervention group
Group type: EXPERIMENTAL
Intervention: Operand format switched across trials (digits or words) with operator alternating between blocks.
Number of subjects: 84
Study 22686162 — intervention group
Group type: COMPARATOR
Intervention: Operator switched across trials, operand format alternated between blocks.
Number of subjects: 84
Study 22686162 — intervention group
Group type: EXPERIMENTAL
Intervention: Digit operands with + when format switched.
Number of subjects: 84
Study 22686162 — intervention group
Group type: EXPERIMENTAL
Intervention: Word problems with operand format blocked.
Number of subjects: 84
Study 20435232 — intervention group
Group type: EXPERIMENTAL
Intervention: Desirudin (15 mg SC q12h for patients without thrombosis; 30 mg SC q12h for patients with thrombosis)
Number of subjects: 16
Study 20435232 — intervention group
Group type: COMPARATOR
Intervention: Argatroban (administered by continuous intravenous infusion according to approved prescribing information or institutional guidelines)
Number of subjects: 16
Study 20435232 — intervention group
Group type: EXPERIMENTAL
Intervention: Desirudin
Number of subjects: 16
Study 20435232 — intervention group
Group type: COMPARATOR
Intervention: Argatroban
Number of subjects: 16
Study 20435232 — intervention group
Group type: EXPERIMENTAL
Intervention: Desirudin and Argatroban
Number of subjects: 16
Study 18922983 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity monitoring (sedentary vs. less sedentary)
Number of subjects: 24
Study 18922983 — intervention group
Group type: COMPARATOR
Intervention: Antihypertensive drugs
Number of subjects: 24
Study 18922983 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring during 12 a.m. to 8 a.m.
Number of subjects: 24
Study 18922983 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep activity levels in nondippers vs. dippers
Number of subjects: 24
Study 15852624 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 8 mg
Number of subjects: 20
Study 15852624 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 20
Study 12452228 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (15 mg/kg intravenously before skin incision and a second bolus of 15 mg/kg at the end of CPB)
Number of subjects: 67
Study 12452228 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo (administered at the end of CPB)
Number of subjects: 67
Study 12452228 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 67
Study 12452228 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 67
Study 11192338 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep hygiene plus bed restriction (restricting time in bed by 30 minutes nightly for one year)
Number of subjects: 21
Study 11192338 — intervention group
Group type: COMPARATOR
Intervention: Sleep hygiene alone
Number of subjects: 21
Study 9391292 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibopamine 100 mg three times daily
Number of subjects: 266
Study 9391292 — intervention group
Group type: COMPARATOR
Intervention: Captopril 25 mg three times daily
Number of subjects: 266
Study 9391292 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 266
Study 8134321 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational plus behavioral strategies (goal-setting, self-monitoring, positive reinforcement, telephone follow-up at 2, 4, 6 and 12 weeks)
Number of subjects: 54
Study 8134321 — intervention group
Group type: COMPARATOR
Intervention: Educational strategies alone (providing verbal and written information, tailoring to individuals' needs, collaborating with patients)
Number of subjects: 54
Study 3440095 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning dosing of theophylline
Number of subjects: 13
Study 3440095 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening dosing of theophylline
Number of subjects: 13
Study 3440095 — intervention group
Group type: EXPERIMENTAL
Intervention: Both morning and evening dosing of theophylline
Number of subjects: 13
Study 30040765 — intervention group
Group type: EXPERIMENTAL
Intervention: Vestibular rehabilitation (VR) training for 4 weeks
Number of subjects: 25
Study 30040765 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 25
Study 30040765 — intervention group
Group type: COMPARATOR
Intervention: Between-group comparison
Number of subjects: 25
Study 28045720 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of obesity and hypertension
Number of subjects: 379
Study 28045720 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of diabetes, hypertension, obesity, and their combinations (dyads, triads, quads)
Number of subjects: 379
Study 24880000 — intervention group
Group type: EXPERIMENTAL
Intervention: EMPOWER intervention (hospice staff education, screening of barriers, discussions with caregivers and patients)
Number of subjects: 126
Study 24880000 — intervention group
Group type: EXPERIMENTAL
Intervention: EMPOWER intervention
Number of subjects: 126
Study 23277296 — intervention group
Group type: EXPERIMENTAL
Intervention: MEO approach
Number of subjects: 80
Study 23277296 — intervention group
Group type: EXPERIMENTAL
Intervention: LEO approach
Number of subjects: 80
Study 21622676 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingent Paid Training group
Number of subjects: 124
Study 21622676 — intervention group
Group type: COMPARATOR
Intervention: Paid Training group
Number of subjects: 124
Study 21622676 — intervention group
Group type: COMPARATOR
Intervention: Unpaid Training group
Number of subjects: 124
Study 18606622 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.36% glucose instillation (A)
Number of subjects: 22
Study 18606622 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.86% glucose instillation (B)
Number of subjects: 22
Study 16926313 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct bonding technique
Number of subjects: 33
Study 16926313 — intervention group
Group type: COMPARATOR
Intervention: Indirect bonding technique
Number of subjects: 33
Study 12623326 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of tea catechin extracts (3.7 g/L catechins, 43% epigallocatechin gallate), three times daily for four weeks.
Number of subjects: 24
Study 12623326 — intervention group
Group type: COMPARATOR
Intervention: Inhalation of saline/bromhexine alone (control group).
Number of subjects: 24
Study 12623326 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of tea catechin extracts.
Number of subjects: 24
Study 10874805 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercially pure titanium implants
Number of subjects: 59
Study 10874805 — intervention group
Group type: EXPERIMENTAL
Intervention: Coated implants
Number of subjects: 59
Study 10874805 — intervention group
Group type: EXPERIMENTAL
Intervention: Implant sites
Number of subjects: 59
Study 10874805 — intervention group
Group type: COMPARATOR
Intervention: Control sites
Number of subjects: 59
Study 9169208 — intervention group
Group type: EXPERIMENTAL
Intervention: Presentation of compounds with conflicting reinforcement histories
Number of subjects: 0
Study 9169208 — intervention group
Group type: COMPARATOR
Intervention: Presentation of compounds containing some or all novel components
Number of subjects: 0
Study 9169208 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple testing procedures
Number of subjects: 0
Study 8249176 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-2 plus low-dose MPA (500 mg orally one day/week)
Number of subjects: 30
Study 8249176 — intervention group
Group type: COMPARATOR
Intervention: IL-2 alone (3 million IU twice/day for 5 days/month subcutaneously)
Number of subjects: 30
Study 8249176 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-2 plus low-dose MPA
Number of subjects: 30
Study 29359677 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutraceuticals for erectile dysfunction
Number of subjects: 74
Study 28437237 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermia as adjunctive therapy to PCI
Number of subjects: 119
Study 28437237 — intervention group
Group type: COMPARATOR
Intervention: Standard care with PCI only
Number of subjects: 119
Study 26256131 — intervention group
Group type: EXPERIMENTAL
Intervention: Punica granatum peel extract (6 g of dry peel/day)
Number of subjects: 0
Study 26256131 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23299764 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline (8 mg)
Number of subjects: 10
Study 23299764 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 21252645 — intervention group
Group type: EXPERIMENTAL
Intervention: Wrapped warm footbath (WW-footbath)
Number of subjects: 18
Study 18616538 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional bleomycin
Number of subjects: 0
Study 16710647 — intervention group
Group type: COMPARATOR
Intervention: Pulsed infrared light therapy (PILT) administered to one foot, 24 treatments (3 times/week for 8 weeks, 30 min each).
Number of subjects: 22
Study 16710647 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment) on the other foot.
Number of subjects: 22
Study 14562491 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention (weekly psychoeducation classes focused on nutrition, exercise, and healthy lifestyle)
Number of subjects: 70
Study 14562491 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 70
Study 10758470 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural diamorphine 2.5 mg followed by PCA bolus 1 mg with a 20‐min lockout (Gp1)
Number of subjects: 0
Study 10758470 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous diamorphine 2.5 mg followed by PCA bolus with a 10‐min lockout period (Gp2)
Number of subjects: 0
Study 10758470 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural diamorphine 2.5 mg in 4 mL of 0.125% (w/v) bupivacaine followed by PCA bolus of 1 mg diamorphine in 4 mL 0.125% (w/v) bupivacaine with a 20‐min lockout (Gp3)
Number of subjects: 0
Study 8642363 — intervention group
Group type: EXPERIMENTAL
Intervention: Bodily amplification and daily life stress interaction at inception
Number of subjects: 67
Study 8642363 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-step model including bodily amplification, daily life stress, age, and education level
Number of subjects: 67
Study 8642363 — intervention group
Group type: EXPERIMENTAL
Intervention: Bodily amplification and daily irritants interaction at baseline
Number of subjects: 67
Study 8642363 — intervention group
Group type: EXPERIMENTAL
Intervention: Total number of ventricular premature contractions during monitoring
Number of subjects: 67
Study 1329683 — intervention group
Group type: EXPERIMENTAL
Intervention: Handsewn ileoanal anastomosis (IAA) with a defunctioning loop ileostomy (Group I)
Number of subjects: 483
Study 1329683 — intervention group
Group type: EXPERIMENTAL
Intervention: Stapled IAA with a defunctioning ileostomy (Group II)
Number of subjects: 483
Study 1329683 — intervention group
Group type: EXPERIMENTAL
Intervention: Stapled IAA with no covering ileostomy (Group III)
Number of subjects: 483
Study 1329683 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with healed IAA after a leak
Number of subjects: 483
Study 1329683 — intervention group
Group type: COMPARATOR
Intervention: Patients with omitted ileostomy
Number of subjects: 483
Study 4018501 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 10 mg
Number of subjects: 15
Study 4018501 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 20 mg
Number of subjects: 15
Study 4018501 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 30 mg
Number of subjects: 15
Study 4018501 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (all doses)
Number of subjects: 15
Study 4018501 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 30585532 — intervention group
Group type: EXPERIMENTAL
Intervention: Mothering from the Inside Out (MIO)
Number of subjects: 15
Study 30585532 — intervention group
Group type: COMPARATOR
Intervention: Parent Education (PE)
Number of subjects: 15
Study 29760027 — intervention group
Group type: EXPERIMENTAL
Intervention: V1SAGES case management intervention
Number of subjects: 247
Study 29760027 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 247
Study 27620899 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 191
Study 27620899 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 191
Study 27620899 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 191
Study 27620899 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 191
Study 27620899 — intervention group
Group type: EXPERIMENTAL
Intervention: FLI score ≥60
Number of subjects: 191
Study 23973795 — intervention group
Group type: EXPERIMENTAL
Intervention: Early feeding starting on day 2 after birth
Number of subjects: 404
Study 23973795 — intervention group
Group type: COMPARATOR
Intervention: Late feeding starting on day 6 after birth
Number of subjects: 404
Study 23973795 — intervention group
Group type: EXPERIMENTAL
Intervention: Infants <29 weeks
Number of subjects: 404
Study 22394666 — intervention group
Group type: EXPERIMENTAL
Intervention: Health mentoring by trained general practice nurses
Number of subjects: 19
Study 20345272 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid-coated (triamcinolone acetonide 1%) 18F hydrophilic dilatation catheter for 2 weeks
Number of subjects: 45
Study 20345272 — intervention group
Group type: EXPERIMENTAL
Intervention: 18F hydrophilic dilatation catheter for 2 weeks
Number of subjects: 45
Study 20345272 — intervention group
Group type: COMPARATOR
Intervention: 18F silicone urethral catheter for 3 days
Number of subjects: 45
Study 17127776 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal midazolam (0.2 mg/Kg)
Number of subjects: 125
Study 17127776 — intervention group
Group type: COMPARATOR
Intervention: Intravenous diazepam (0.3 mg/Kg)
Number of subjects: 125
Study 15530132 — intervention group
Group type: COMPARATOR
Intervention: Single oral doses of L-T4 tablets (25, 50, 75, 100, 125, 150, 175, 200 microg per tablet; total doses 600, 625 or 700 microg)
Number of subjects: 169
Study 15530132 — intervention group
Group type: COMPARATOR
Intervention: Liquid formulation of L-T4
Number of subjects: 169
Study 11587406 — intervention group
Group type: EXPERIMENTAL
Intervention: Failed renal transplant patients (fTx)
Number of subjects: 42
Study 11587406 — intervention group
Group type: COMPARATOR
Intervention: Never-transplanted PD patients (non-Tx)
Number of subjects: 42
Study 9303630 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatic intraarterial cisplatin + hyaluronidase
Number of subjects: 10
Study 9303630 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin alone
Number of subjects: 10
Study 8281530 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 20
Study 8281530 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 20
Study 3471936 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral methotrexate (n = 11)
Number of subjects: 12
Study 3471936 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular methotrexate (n = 7)
Number of subjects: 12
Study 3471936 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral methotrexate (dosages ≤ 40 mg/m2)
Number of subjects: 12
Study 3471936 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral methotrexate (dosages > 40 mg/m2)
Number of subjects: 12
Study 31978697 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal steroids (INS)
Number of subjects: 267
Study 31978697 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihistamine (ATH) combined with leukotriene receptor antagonists (LRA)
Number of subjects: 267
Study 31978697 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 267
Study 31819385 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi exercise (weekly classes and home practice for 20 weeks)
Number of subjects: 85
Study 31819385 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 85
Study 27736289 — intervention group
Group type: EXPERIMENTAL
Intervention: Foam Rolling
Number of subjects: 30